Sanofi (Euronext: SAN) and Regeneron (Nasdaq: REGN) intend to sidestep the pressures of the crowded PD-1 field by aiming for a first cemiplimab approval in cutaneous squamous cell carcinoma (CSCC), which does not yet have any marketed checkpoint inhibitors, says life sciences analytics company GlobalData.
Approval of Sanofi and Regeneron’s cemiplimab PD-1 checkpoint inhibitor is expected in CSCC from the US Food and Drug Administration (FDA) in October 2018 and the European Medicines Agency (EMA) in Q1 2019.
"Cemiplimab would face challenges in successfully eroding market share from other products"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze